The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
Official Title: Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women With Previously Untreated
Study ID: NCT00548899
Brief Summary: The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer
Detailed Description: Epirubicin/Cyclophosphamide followed by Paclitaxel (EC/P) is a well tolerated regimen with high clinical activity. Histopathological complete remission after preoperative chemotherapy has a direct correlation with the disease-free and overall survival. The aim of combining a chemotherapy regime with sorafenib in the neoadjuvant setting is to increase the locoregional and systemic outcome of these patients
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
St. Gertrauden Krankenhaus, Berlin, , Germany
Klinikum der J. W. Goethe Universität, Frankfurt am Main, , Germany
Henriettenstiftung, Hannover, , Germany
Elisabeth Krankenhaus, Kassel, , Germany
Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, , Germany
Klinikum der Universität zu Köln, Köln, , Germany
Klinikum Offenbach, Offenbach, , Germany
Klinikum Südstadt, Rostock, , Germany
Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, , Germany
Name: Sibylle Loibl, MD
Affiliation: GBG Forschungs GmbH
Role: STUDY_CHAIR